Published in Oncotarget on January 17, 2017
The molecular mechanisms of chemoresistance in cancers. Oncotarget (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
TOR signaling in growth and metabolism. Cell (2006) 35.29
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Cancer. p53, guardian of the genome. Nature (1992) 16.36
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 14.03
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev (2001) 14.02
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
DNA mismatch repair. Annu Rev Biochem (2005) 8.21
Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer (2004) 7.91
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol (2014) 5.97
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol (2005) 4.71
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68
Molecular mechanisms of drug resistance. J Pathol (2005) 4.60
American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin (2001) 4.41
Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res (1997) 4.32
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence. FEBS J (2009) 4.05
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (2007) 3.96
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 3.89
Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res (2005) 3.79
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 3.37
Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells (2009) 3.25
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
Mechanisms of Taxol resistance related to microtubules. Oncogene (2003) 3.16
Platinum resistance: the role of DNA repair pathways. Clin Cancer Res (2008) 3.16
Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet (2001) 2.98
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89
Retracted Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem (2003) 2.89
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell (2009) 2.80
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol (2014) 2.72
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res (2007) 2.58
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther (2009) 2.50
Recurrent epithelial ovarian cancer: an update on treatment. Oncology (Williston Park) (2013) 2.37
PTEN: a new guardian of the genome. Oncogene (2008) 2.37
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol (2015) 2.30
XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res (2001) 2.25
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life (2006) 2.24
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2.20
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol (2014) 2.18
Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res (2006) 2.17
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev (1998) 2.11
The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci (1993) 2.04
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem (1996) 2.01
Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res (2000) 1.99
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res (2002) 1.98
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest (1994) 1.97
Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol (2006) 1.97
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res (1998) 1.97
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem (2003) 1.95
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res (2001) 1.95
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer (2010) 1.85
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med (2010) 1.82
A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene (1999) 1.80
The tumor microenvironment at a glance. J Cell Sci (2012) 1.79
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res (2007) 1.76
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res (2007) 1.72
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72
Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res (2000) 1.70
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol (2005) 1.69
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene (1997) 1.67
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol (2005) 1.67
p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res (2003) 1.62
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest (1991) 1.62